Bullous Systemic Lupus Erythematosus (BSLE) Medication

1. Poojary S, Rais S. Bullous systemic lupus erythematosus with lupus nephritis: a rare case of a subepidermal bullous disorder in a child. Cutis. 2012 Jan. 89(1):17-21. [QxMD MEDLINE Link].

2. de Risi-Pugliese T, Cohen Aubart F, Haroche J, Moguelet P, Grootenboer-Mignot S, Mathian A, et al. Clinical, histological, immunological presentations and outcomes of bullous systemic lupus erythematosus: 10 New cases and a literature review of 118 cases. Semin Arthritis Rheum. 2017 Nov 4. [QxMD MEDLINE Link].

3. Lee HJ, Yun SJ, Lee SC, Lee JB. A Case of Linear IgA Bullous Dermatosis Associated with Systemic Lupus Erythematosus. Ann Dermatol. 2016 Oct. 28 (5):660-662. [QxMD MEDLINE Link].

4. Odonwodo A, Vashisht P. Bullous Systemic Lupus Erythematosus. StatPearls [Internet]. 2021 Jan. [QxMD MEDLINE Link]. [Full Text].

5. Daneshpazhooh M, Shahdi M, Aghaeepoor M, Hasiri G, Chams C. A comparative study of antibody titers of blister fluid and serum in patients with subepidermal immunobullous diseases. Int J Dermatol. 2004 May. 43(5):348-51. [QxMD MEDLINE Link].

6. Roustan G, Salas C, Barbadillo C, Sánchez Yus E, Mulero J, Simón A. Lupus erythematosus with an erythema multiforme-like eruption. Eur J Dermatol. 2000 Aug. 10(6):459-62. [QxMD MEDLINE Link].

7. Horne NS, Narayan AR, Young RM, Frieri M. Toxic epidermal necrolysis in systemic lupus erythematosus. Autoimmun Rev. 2006 Feb. 5(2):160-4. [QxMD MEDLINE Link].

8. Mandelcorn R, Shear NH. Lupus-associated toxic epidermal necrolysis: a novel manifestation of lupus?. J Am Acad Dermatol. 2003 Apr. 48(4):525-9. [QxMD MEDLINE Link].

9. Paradela S, Martinez-Gomez W, Fernandez-Jorge B, et al. Toxic epidermal necrolysis-like acute cutaneous lupus erythematosus. Lupus. 2007. 16(9):741-5. [QxMD MEDLINE Link].

10. Yang S, Gao Y, Song Y, Liu J, Yang C, Liu J, et al. The study of the participation of basement membrane zone antibodies in the formation of the lupus band in systemic lupus erythematosus. Int J Dermatol. 2004 Jun. 43(6):420-7. [QxMD MEDLINE Link].

11. Grabell DA, Matthews LA, Yancey KB, Chong BF. Detection of Type VII Collagen Autoantibodies Before the Onset of Bullous Systemic Lupus Erythematosus. JAMA Dermatol. 2015 May. 151 (5):539-43. [QxMD MEDLINE Link]. [Full Text].

12. Ishii N, Yoshida M, Hisamatsu Y, et al. Epidermolysis bullosa acquisita sera react with distinct epitopes on the NC1 and NC2 domains of type VII collagen: study using immunoblotting of domain-specific recombinant proteins and postembedding immunoelectron microscopy. Br J Dermatol. 2004 May. 150(5):843-51. [QxMD MEDLINE Link].

13. Chen M, Doostan A, Bandyopadhyay P, et al. The cartilage matrix protein subdomain of type VII collagen is pathogenic for epidermolysis bullosa acquisita. Am J Pathol. 2007 Jun. 170(6):2009-18. [QxMD MEDLINE Link]. [Full Text].

14. Woodley DT, Ram R, Doostan A, et al. Induction of epidermolysis bullosa acquisita in mice by passive transfer of autoantibodies from patients. J Invest Dermatol. 2006 Jun. 126(6):1323-30. [QxMD MEDLINE Link].

15. Chen L, Peterson JD, Zheng WY, Lin SX, Chan LS. Autoimmunity to type VII collagen in SKH1 mice is independent of regulatory T cells. Clin Exp Immunol. 2006 Aug. 145(2):322-31. [QxMD MEDLINE Link]. [Full Text].

16. Chan LS, Lapiere JC, Chen M, et al. Bullous systemic lupus erythematosus with autoantibodies recognizing multiple skin basement membrane components, bullous pemphigoid antigen 1, laminin-5, laminin-6, and type VII collagen. Arch Dermatol. 1999 May. 135(5):569-73. [QxMD MEDLINE Link].

17. Chen M, Chan LS, Cai X, et al. Development of an ELISA for rapid detection of anti-type VII collagen autoantibodies in epidermolysis bullosa acquisita. J Invest Dermatol. 1997 Jan. 108(1):68-72. [QxMD MEDLINE Link].

18. Fujii K, Fujimoto W, Ueda M, Makino E, Arata J. Detection of anti-type VII collagen antibody in Sjögren's syndrome/lupus erythematosus overlap syndrome with transient bullous systemic lupus erythematosus. Br J Dermatol. 1998 Aug. 139(2):302-6. [QxMD MEDLINE Link].

19. Hertl M, Eming R, Veldman C. T cell control in autoimmune bullous skin disorders. J Clin Invest. 2006 May. 116(5):1159-66. [QxMD MEDLINE Link]. [Full Text].

20. Ting W, Stone MS, Racila D, Scofield RH, Sontheimer RD. Toxic epidermal necrolysis-like acute cutaneous lupus erythematosus and the spectrum of the acute syndrome of apoptotic pan-epidermolysis (ASAP): a case report, concept review and proposal for new classification of lupus erythematosus vesiculobullous skin lesions. Lupus. 2004. 13(12):941-50. [QxMD MEDLINE Link].

21. Nasongkhla P, Pratchyapruit W, Tagami H. Bullous systemic lupus erythematosus induced by UVB: report a case. J Med Assoc Thai. 2012 Jul. 95(7):969-73. [QxMD MEDLINE Link].

22. Boddu P, Nadiri M, Malik O. Diffuse Bullous Eruptions in an Elderly Woman: Late-Onset Bullous Systemic Lupus Erythematosus. Case Rep Dermatol. 2016 Sep-Dec. 8 (3):278-282. [QxMD MEDLINE Link].

23. Li AW, Weed JG, Stamey CR, Subtil A, Tomayko MM, Antaya RJ. Bullous systemic lupus erythematosus in a 6-year-old boy. Pediatr Dermatol. 2017 Nov. 34 (6):e313-e316. [QxMD MEDLINE Link].

24. Hasbún Z MT, Rollan MP, Chaparro R X, Fischer S C, Castrillón V A, González B S, et al. Bullous systemic lupus erythematosus: An uncommon manifestation in pediatric population. Andes Pediatr. 2021 Jun. 92 (3):428-433. [QxMD MEDLINE Link].

25. Chanprapaph K, Sawatwarakul S, Vachiramon V. A 12-year retrospective review of bullous systemic lupus erythematosus in cutaneous and systemic lupus erythematosus patients. Lupus. 2017 Oct. 26 (12):1278-1284. [QxMD MEDLINE Link].

26. Lourenço DM, Gomes RC, Aikawa NE, Campos LM, Romiti R, Silva CA. Childhood-onset bullous systemic lupus erythematosus. Lupus. 2014 Nov. 23 (13):1422-5. [QxMD MEDLINE Link].

27. Yogarajah M, Sivasambu B, Jaffe EA. Bullous systemic lupus erythematosus associated with esophagitis dissecans superficialis. Case Rep Rheumatol. 2015. 2015:930683. [QxMD MEDLINE Link]. [Full Text].

28. Khandpur S, Das S, Singh MK. Rowell's syndrome revisited: report of two cases from India. Int J Dermatol. 2005 Jul. 44(7):545-9. [QxMD MEDLINE Link].

29. Pandhi D, Singal A, Agarwal P. Rowell's syndrome and associated antiphospholipid syndrome. Clin Exp Dermatol. 2004 Jan. 29(1):22-4. [QxMD MEDLINE Link].

30. Shteyngarts AR, Warner MR, Camisa C. Lupus erythematosus associated with erythema multiforme: does Rowell's syndrome exist?. J Am Acad Dermatol. 1999 May. 40(5 Pt 1):773-7. [QxMD MEDLINE Link].

31. Zeitouni NC, Funaro D, Cloutier RA, Gagné E, Claveau J. Redefining Rowell's syndrome. Br J Dermatol. 2000 Feb. 142(2):343-6. [QxMD MEDLINE Link].

32. Paradela S, Martínez-Gómez W, Fernández-Jorge B, et al. Toxic epidermal necrolysis-like acute cutaneous lupus erythematosus. Lupus. 2007. 16(9):741-5. [QxMD MEDLINE Link].

33. Gammon WR, Fine JD, Forbes M, Briggaman RA. Immunofluorescence on split skin for the detection and differentiation of basement membrane zone autoantibodies. J Am Acad Dermatol. 1992 Jul. 27(1):79-87. [QxMD MEDLINE Link].

34. Maggio MC, Corsello G, Prinzi E, Cimaz R. Systemic Lupus Erythematosus and Bullous Pemphigoid with Dramatic Response to Dapsone. Am J Case Rep. 2017 Mar 29. 18:317-319. [QxMD MEDLINE Link].

35. Malcangi G, Brandozzi G, Giangiacomi M, Zampetti M, Danieli MG. Bullous SLE: response to methotrexate and relationship with disease activity. Lupus. 2003. 12(1):63-6. [QxMD MEDLINE Link].

36. Alsanafi S, Kovarik C, Mermelstein AL, Werth VP. Rituximab in the treatment of bullous systemic lupus erythematosus. J Clin Rheumatol. 2011 Apr. 17(3):142-4. [QxMD MEDLINE Link].

37. Hamminga EA, Vermeer MH. Bullous systemic lupus erythematosus responding to mycophenolate mofetil. Eur J Dermatol. 2010 Nov-Dec. 20(6):844-5. [QxMD MEDLINE Link].

38. Anyanwu CO, Ang CC, Werth VP. Oral mucosal involvement in bullous lupus. Arthritis Rheum. 2013 Oct. 65 (10):2622. [QxMD MEDLINE Link].

39. Hoffmann JHO, Enk AH. High-dose intravenous immunoglobulins for the treatment of dermatological autoimmune diseases. J Dtsch Dermatol Ges. 2017 Dec. 15 (12):1211-1226. [QxMD MEDLINE Link].

40. Juhász M, Rogge M, Chen M, Czernik A, Jung Kim S, Geller L. Case of Pediatric Bullous Systemic Lupus Erythematosus Treated with Intravenous Immunoglobulin. Pediatr Dermatol. 2017 Jan. 34 (1):e54-e56. [QxMD MEDLINE Link].

41. Wu EY, Schanberg LE, Wershba EC, Rabinovich CE. Lenalidomide for refractory cutaneous manifestations of pediatric systemic lupus erythematosus. Lupus. 2017 May. 26 (6):646-649. [QxMD MEDLINE Link].

Sarah Sweeney Pinney, MD, FAAD Dermatologist, Clear Dermatology

Sarah Sweeney Pinney, MD, FAAD is a member of the following medical societies: American Academy of Dermatology, Texas Dermatological Society, Texas Medical Association, Women's Dermatologic Society

Disclosure: Nothing to disclose.

Dirk M Elston, MD Professor and Chairman, Department of Dermatology and Dermatologic Surgery, Medical University of South Carolina College of Medicine

Dirk M Elston, MD is a member of the following medical societies: American Academy of Dermatology

Disclosure: Nothing to disclose.

Julie V Schaffer, MD Assistant Professor of Dermatology and Pediatrics, Director of Dermatology Resident Education, Director of Pediatric Dermatology Unit, New York University School of Medicine

Disclosure: Nothing to disclose.

Hillary D Johnson-Jahangir, MD, PhD Clinical Assistant Professor, Department of Dermatology, University of Iowa, Roy J and Lucille A Carver College of Medicine

Hillary D Johnson-Jahangir, MD, PhD is a member of the following medical societies: American College of Mohs Surgery, American Medical Association, American Society for Dermatologic Surgery, American Society for Laser Medicine and Surgery, Iowa Medical Society

Disclosure: Nothing to disclose.

Ivan D Camacho, MD Dermatologist, Private Practice; Voluntary Assistant Professor of Dermatology, Department of Dermatology and Cutaneous Surgery, University of Miami, Leonard M Miller School of Medicine

Ivan D Camacho, MD is a member of the following medical societies: American Academy of Dermatology, American Medical Association, American Society for Dermatologic Surgery, American Society for MOHS Surgery, Florida Medical Association, International Society of Dermatology, Women's Dermatologic Society

Disclosure: Nothing to disclose.

Alice L Ye Medical Student, University of Iowa, Carver College of Medicine

Disclosure: Nothing to disclose.

Colleen A O'Neill University of Texas Health Science Center at Houston, McGovern Medical School

Disclosure: Nothing to disclose.

Caroline T Starling University of Texas Health Science Center at Houston, McGovern Medical School

Disclosure: Nothing to disclose.

Jeffrey P Callen, MD Professor of Medicine (Dermatology), Chief, Division of Dermatology, University of Louisville School of Medicine

Jeffrey P Callen, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Dermatology, American College of Physicians, and American College of Rheumatology

Disclosure: Amgen Honoraria Consulting; Abbott Honoraria Consulting; Electrical Optical Sciences Consulting fee Consulting; Celgene Honoraria Safety Monitoring Committee; GSK - Glaxo Smith Kline Consulting fee Consulting; TenXBioPharma Consulting fee Safety Monitoring Committee

Michael Girardi, MD Associate Professor and Residency Director, Department of Dermatology, Yale University School of Medicine

Michael Girardi, MD is a member of the following medical societies: American Academy of Dermatology and Society for Investigative Dermatology

Disclosure: Nothing to disclose.

Michael J Wells, MD Associate Professor, Department of Dermatology, Texas Tech University Health Sciences Center, Paul L Foster School of Medicine

Michael J Wells, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Dermatology, American Medical Association, and Texas Medical Association

Disclosure: Nothing to disclose.

• Print this section
• Print the entire contents of
• Print the entire contents of article